Haisco Pharmaceutical Hits Day Low at CNY 44.39 Amid Price Pressure

Haisco Pharmaceutical Group Co., Ltd. experienced a notable decline in its stock performance today, with a decrease of 3.06%. The stock reached an intraday low of CNY 44.39, reflecting a challenging trading environment. Over the past week, Haisco has seen a more significant drop of 6.29%, contrasting with a slight gain of 0.41% in the China Shanghai Composite index during the same period. In terms of longer-term performance, Haisco's stock has shown a year-to-date decline of 12.35%, while the broader market has gained 2.85%. Despite a robust annual performance of 34.35% over the past year, the company's growth metrics indicate a mixed picture, with net sales increasing at an annual rate of only 2.89% over the last five years. The company's market capitalization stands at CNY 25,698 million, categorizing it as a large-cap entity within the pharmaceuticals and biotechnology industry. Haisco's current price-to-earnings ratio is notably high at 141.00, and it maintains a dividend yield of 0.59%. These financial indicators suggest a complex landscape for Haisco Pharmaceutical Group as it navigates current market conditions.